Abstract #1986

DW-MRI for evaluating lesions classified as responding and non-responding on RECIST criteria in patients with relapsed epithelial ovarian and primary peritoneal cancer re-challenged with platinum-based chemotherapy

Jennifer C Wakefield^1,2, Jessica M Winfield^1,2, Veronica Morgan², Alison MacDonald², Susana Banerjee^1,2, Andrew N Priest³, Rebecca A Quest⁴, Susan Freeman³, Andrea G Rockall⁴, and Nandita M deSouza^1,2

¹Division of Radiotherapy and Imaging, Cancer Research UK Cancer Imaging Centre, The Institute of Cancer Research, London, United Kingdom, ²The Royal Marsden Hospital, Sutton, United Kingdom, ³Department of Radiology, Addenbrooke’s Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom, ⁴Imaging Department, Imperial College Healthcare NHS Trust, London, United Kingdom

The utility of Diffusion-weighted MRI (DW-MRI) in defining response by volume reduction or for determining the time-course of apparent diffusion coefficient (ADC) changes indicative of response has not been evaluated in patients with relapsed ovarian or peritoneal cancer. We evaluated post-treatment change in volume and ADC in lesions classified by RECIST criteria as responders and non-responders. We found responding lesions show greater change in volume and equivalent change in ADC to non-responding lesions after one cycle of chemotherapy. In non-responding lesions, the change in these parameters continued at the same rate post-first cycle of chemotherapy, indicating a delayed response.

This abstract and the presentation materials are available to members only; a login is required.

Join Here